Jafron Biomedical Co Receivables
The Accounts Receivable of Jafron Biomedical Co (300529.SZ) as of Oct 14, 2026 is 53.46 M CNY. In the previous year, Accounts Receivable was 74.85 M CNY — a change of -28.58% (lower).
Get this data via API
Financial Data API
Receivables
53.46 MCNY
YoY
-28.58%
Last updated:
The Jafron Biomedical Co Receivables history
3 Years
10 Years
25 Years
Max
| YEAR | Receivables | YoY |
|---|---|---|
| 53.46 MCNY | -28.58% | |
| 74.85 MCNY | -66.24% | |
| 221.73 MCNY | -17.60% | |
| 269.09 MCNY | +60.75% | |
| 167.40 MCNY | +5.75% | |
| 158.30 MCNY | +24.45% | |
| 127.20 MCNY | +19.77% | |
| 106.20 MCNY | +40.85% | |
| 75.40 MCNY | +44.72% | |
| 52.10 MCNY | +41.58% | |
| 36.80 MCNY | — |
Jafron Biomedical Co Stock analysis
Frequently Asked Questions about Jafron Biomedical Co stock
Accounts Receivable of Jafron Biomedical Co is 53.46 M CNY in 2024.
Accounts Receivable of Jafron Biomedical Co changed from 74.85 M CNY to 53.46 M CNY, representing a -28.58% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of Accounts Receivable Jafron Biomedical Co since 2006 – with annual values, charts, and detailed analysis.
Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.
Accounts Receivable's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Jafron Biomedical Co historically and in real time.
Balance Sheet — Jafron Biomedical Co
All Key Metrics — Jafron Biomedical Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth